• 1
    Fratzl P, Gupta HS, Paschalis EP, Roschger P 2004 Structure and mechanical quality of the collagen-mineral composite in bone. J Mater Chem 14: 21152123.
  • 2
    Faulkner KG 2000 Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 15: 183187.
  • 3
    Veenland JF, Link TM, Konermann W, Meier N, Grashuis JL, Gelsema ES 1997 Unraveling the role of structure and density in determining vertebral bone strength. Calcif Tissue Int 61: 474479.
  • 4
    Melton LJI, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL 2000 Determinants of bone loss from the femoral neck in women of different ages. J Bone Miner Res 15: 2431.
  • 5
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 12541259.
  • 6
    Cummings SR 1985 Are patients with hip fractures more osteoporotic? Review of the evidence. Am J Med 78: 487494.
  • 7
    Cummings SR, Bates D, Black DM 2002 Clinical use of bone densitometry: Scientific review. JAMA 288: 18891897.
  • 8
    Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17: 110.
  • 9
    Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, van Staa TP, Adachi JD 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: Greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7: 255261.
  • 10
    Watts N, Geusens P, Barton I, Felsenberg D 2005 Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: Reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 20: 20972104.
  • 11
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282: 13441352.
  • 12
    Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ 2002 Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17: 11391147.
  • 13
    Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD 2004 Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34: 736746.
  • 14
    Eriksen EF, Melsen F, Sod E, Barton I, Chines A 2002 Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31: 620625.
  • 15
    Gordon MS, Gordon MB 2002 Response of bone mineral density to once-weekly administration of risedronate. Endocr Pract 8: 202207.
  • 16
    Ste-Marie LG, Sod E, Johnson T, Chines A 2004 Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 75: 469476.
  • 17
    Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88: 542549.
  • 18
    Marcott C, Reeder RC, Paschalis EP, Tatakis DN, Boskey AL, Mendelsohn R 1998 Infrared microspectroscopic imaging of biomineralized tissues using a mercury-cadmium-telluride focal-plane array detector. Cell Mol Biol 44: 109115.
  • 19
    Mendelsohn R, Paschalis EP, Boskey AL 1999 Infrared spectroscopy, microscopy, and microscopic imaging of mineralizing tissues. Spectra-structure correlations from human iliac crest biopsies. J Biomed Opt 4: 1421.
  • 20
    Paschalis EP, Verdelis K, Doty SB, Boskey AL, Mendelsohn R, Yamauchi M 2001 Spectroscopic characterization of collagen cross-links in bone. J Bone Miner Res 16: 18211828.
  • 21
    Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL 1997 FTIR microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tissue Int 61: 480486.
  • 22
    Paschalis EP, Betts F, DiCarlo E, Mendelsohn R, Boskey AL 1997 FTIR microspectroscopic analysis of human iliac crest biopsies from untreated osteoporotic bone. Calcif Tissue Int 61: 487492.
  • 23
    Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL 1996 FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int 59: 480487.
  • 24
    Paschalis EP, Recker R, DiCarlo E, Doty SB, Atti E, Boskey AL 2003 Distribution of collagen cross-links in normal human trabecular bone. J Bone Miner Res 18: 19421946.
  • 25
    Paschalis EP, Shane E, Lyritis G, Skarantavos G, Mendelsohn R, Boskey AL 2004 Bone fragility and collagen cross-links. J Bone Miner Res 19: 20002004.
    Direct Link:
  • 26
    Paschalis EP, Glass EV, Donley DW, Eriksen EF 2005 Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: New results from the Fracture Prevention Trial. J Clin Endocrinol Metab 90: 46444649.
  • 27
    Paschalis EP, Burr DB, Mendelsohn R, Hock JM, Boskey AL 2003 Bone mineral and collagen quality in humeri of ovariectomized cynomolgus monkeys given rhPTH(1–34) for 18 months. J Bone Miner Res 18: 769775.
  • 28
    Paschalis EP, Boskey AL, Kassem M, Eriksen EF 2003 Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 18: 955959.
  • 29
    Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH 1999 Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties. J Bone Miner Res 14: 17681778.
  • 30
    Aparicio S, Doty SB, Camacho NP, Paschalis EP, Spevak L, Mendelsohn R, Boskey AL 2002 Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. Calcif Tissue Int 70: 422429.
  • 31
    Roschger P, Fratzl P, Eschberger J, Klaushofer K 1998 Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 23: 319326.
  • 32
    Schenk RK, Olah AJ, Herrmann W 1984 Preparation of calcified tissues for light microscopy. DicksonGR (ed.) Methods of Calcified Tissue Preparation. Elsevier, New York, NY, USA, 156.
  • 33
    Dong A, Huang P, Caughey WS 1990 Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29: 33033308.
  • 34
    Mendelsohn R, Paschalis EP, Sherman PJ, Boskey AL 2000 IR microscopic imaging of pathological states and fracture healing of bone. Appl Spectrosc 54: 11831191.
  • 35
    Gao H, Ji B, Jager IL, Arzt E, Fratzl P 2003 Materials become insensitive to flaws at nanoscale: Lessons from nature. Proc Natl Acad Sci USA 100: 55975600.
  • 36
    Jager I, Fratzl P 2000 Mineralized collagen fibrils: A mechanical model with a staggered arrangement of mineral particles. Biophys J 79: 17371746.
  • 37
    Fratzl P, Roschger P, Eschberger J, Abendroth B, Klaushofer K 1994 Abnormal bone mineralization after fluoride treatment in osteoporosis: A small-angle x-ray-scattering study. J Bone Miner Res 9: 15411549.
  • 38
    Yamauchi M 1996 Collagen: The major matrix molecule in mineralized tissues. AndersonJJB, GarnerSC (eds.) Calcium and Phosphorus in Health and Disease. CRC Press, New York, NY, USA, 127141.
  • 39
    Kuypers R, Tyler M, Kurth LB, Jenkins ID, Hogan DJ 1992 Identification of the loci of the collagen-associated Ehrlich chromogen in type I collagen confirms its role as a trivalent cross-link. Biochem J 283: 129136.
  • 40
    Knott L, Tarlton JF, Bailey AJ 1997 Chemistry of collagen cross-linking: Biochemical changes in collagen during the partial mineralization of turkey leg tendon. Biochem J 322: 535542.
  • 41
    Dodds RA, Ferris BD 1987 Changes in orientation of non-collagenous bone matrix in osteoporosis. ChristiansenC, JohansenJS, RiisBJ (eds.) Osteoporosis 1987. Osteopress APS, Copenhagen, Denmark, 309312.
  • 42
    Knott L, Whitehead CC, Fleming RH, Bailey AJ 1995 Biochemical changes in the collagenous matrix of osteoporotic avian bone. Biochem J 310: 10451051.
  • 43
    Knott L, Bailey AJ 1998 Collagen cross-links in mineralizing tissues: A review of their chemistry, function, and clinical relevance. Bone 22: 181187.
  • 44
    Bailey AJ, Wotton SF, Sims TJ, Thompson PW 1992 Post-translational modifications in the collagen of human osteoporotic femoral head. Biochem Biophys Res Commun 185: 801805.
  • 45
    Bailey AJ, Wotton SF, Sims TJ, Thompson PW 1993 Biochemical changes in the collagen of human osteoporotic bone matrix. Connect Tissue Res 29: 119132.
  • 46
    Kowitz J, Knippel M, Schuhr T, Mach J 1997 Alteration in the extent of collagen I hydroxylation, isolated from femoral heads of women with a femoral neck fracture caused by osteoporosis. Calcif Tissue Int 60: 501505.
  • 47
    Blank RD, Baldini TH, Kaufman M, Bailey S, Gupta R, Yershov Y, Boskey AL, Coppersmith SN, Demant P, Paschalis EP 2003 Spectroscopically determined collagen Pyr/deH-DHLNL cross-link ratio and crystallinity indices differ markedly in recombinant congenic mice with divergent calculated bone tissue strength. Connect Tissue Res 44: 134142.
  • 48
    Fratzl P, Schreiber S, Roschger P, Lafage MH, Rodan G, Klaushofer K 1996 Effects of sodium fluoride and alendronate on the bone mineral in minipigs: A small-angle X-ray scattering and backscattered electron imaging study. J Bone Miner Res 11: 248253.
  • 49
    Masse PG, Boskey AL, Pritzker KPH, Mendes M, Weiser H 1994 Vitamin B6 deficiency experimentally-induced bone and joint disorder: Microscopic, radiographic and biochemical evidence. Br J Nutr 71: 919932.
  • 50
    Masse PG, Rimnac CM, Yamauchi M, Coburn PS, Rucker BR, Howell SD, Boskey AL 1996 Pyridoxine deficiency affects biomechanical properties of chick tibial bone. Bone 18: 567574.
  • 51
    Oxlund H, Barckman M, Ortoft G, Andreassen TT 1995 Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 17(4 Suppl): 365S371S.
  • 52
    Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH 2006 Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. Bone 38: 617627.
  • 53
    Hein LE, Grassi RL, Roldan EJ, Gregori D, Varela ME, Piccinni EP 1997 Morphological studies of hydroxyapatite crystals exposed to disodium pamidronate. Medicina (B Aires) 57(Suppl 1): 1016.
  • 54
    Rodan GA, Balena R 1993 Bisphosphonates in the treatment of metabolic bone diseases. Ann Med 25: 373378.
  • 55
    Budz JA, Lo Re M, Nancollas GH 1988 The influence of high- and low-molecular-weight inhibitors on dissolution kinetics of hydroxyapatite and human enamel in lactate buffers: A constant composition study. J Dent Res 67: 14931498.
  • 56
    Francis MD, Ferguson DL, Tofe AJ, Bevan JA, Michaels SE 1980 Comparative evaluation of three diphosphonates: In vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J Nucl Med 21: 11851189.
  • 57
    Romanello M, Bivi N, Pines A, Deganuto M, Quadrifoglio F, Moro L, Tell G 2006 Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines. Bone (in press).
  • 58
    Helvering LM, Liu R, Kulkarni NH, Wei T, Chen P, Huang S, Lawrence F, Halladay DL, Miles RR, Ambrose EM, Sato M, Ma YL, Frolik CA, Dow ER, Bryant HU, Onyia JE 2005 Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene. Mol Pharmacol 68: 12251238.